Wed, May 25, 2022
Tue, May 24, 2022
Mon, May 23, 2022
Sat, May 21, 2022
Fri, May 20, 2022
Thu, May 19, 2022

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $110 on, May 23rd, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-110-on-may-23rd-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $134 to $110 on, May 23rd, 2022.

Raghuram has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Corinne Jenkins of "Goldman Sachs" Maintained at Strong Sell with Decreased Target to $10 on, Monday, May 9th, 2022
  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $25 on, Wednesday, February 16th, 2022

Publication Contributing Sources